PL2445489T3 - Kompozycje do leczenia uzależnienia od narkotyków i polepszania zachowania związanego z uzależnieniem - Google Patents
Kompozycje do leczenia uzależnienia od narkotyków i polepszania zachowania związanego z uzależnieniemInfo
- Publication number
- PL2445489T3 PL2445489T3 PL10792277T PL10792277T PL2445489T3 PL 2445489 T3 PL2445489 T3 PL 2445489T3 PL 10792277 T PL10792277 T PL 10792277T PL 10792277 T PL10792277 T PL 10792277T PL 2445489 T3 PL2445489 T3 PL 2445489T3
- Authority
- PL
- Poland
- Prior art keywords
- addiction
- compositions
- improving
- related behavior
- treating drug
- Prior art date
Links
- 206010012335 Dependence Diseases 0.000 title 1
- 206010013663 drug dependence Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/492,566 US8232315B2 (en) | 2009-06-26 | 2009-06-26 | Methods for treating drug addiction and improving addiction-related behavior |
| EP10792277.5A EP2445489B1 (en) | 2009-06-26 | 2010-06-10 | Compositions for treating drug addiction and improving addiction-related behavior |
| PCT/KR2010/003742 WO2010150995A2 (en) | 2009-06-26 | 2010-06-10 | Compositions for treating drug addiction and improving addiction-related behavior |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2445489T3 true PL2445489T3 (pl) | 2020-05-18 |
Family
ID=43381414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10792277T PL2445489T3 (pl) | 2009-06-26 | 2010-06-10 | Kompozycje do leczenia uzależnienia od narkotyków i polepszania zachowania związanego z uzależnieniem |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8232315B2 (pl) |
| EP (2) | EP3552604B1 (pl) |
| JP (1) | JP5650208B2 (pl) |
| KR (1) | KR101461567B1 (pl) |
| CN (2) | CN102695502B (pl) |
| AU (1) | AU2010263469B2 (pl) |
| BR (1) | BRPI1015064A2 (pl) |
| CA (1) | CA2764665C (pl) |
| DK (1) | DK2445489T3 (pl) |
| ES (2) | ES2766272T3 (pl) |
| MX (1) | MX2011013201A (pl) |
| PL (1) | PL2445489T3 (pl) |
| RU (1) | RU2535046C2 (pl) |
| TW (1) | TWI483719B (pl) |
| WO (1) | WO2010150995A2 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1890684T3 (pl) | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
| AU2010270971B2 (en) | 2009-06-22 | 2015-08-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| RU2019114940A (ru) | 2013-03-13 | 2019-06-28 | ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи | Лечение катаплексии |
| CN105848650A (zh) * | 2013-07-12 | 2016-08-10 | 爵士制药国际Iii有限公司 | 促进吸烟停止 |
| DK3021838T3 (da) | 2013-07-18 | 2020-08-24 | Jazz Pharmaceuticals Ireland Ltd | Behandling af fedme |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| TWI655179B (zh) * | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| CN121202730A (zh) | 2016-09-06 | 2025-12-26 | 爱尔兰贾兹制药有限公司 | (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途 |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| JP7074750B2 (ja) | 2016-10-06 | 2022-05-24 | ジャズ ファーマスティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール化合物およびその使用 |
| KR20200016889A (ko) | 2017-06-02 | 2020-02-17 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 과다 졸림증을 치료하기 위한 방법 및 조성물 |
| SG11202000817SA (en) | 2017-07-31 | 2020-02-27 | Jazz Pharmaceuticals Ireland Ltd | Carbamoyl phenylalaninol analogs and uses thereof |
| CN110655500B (zh) * | 2018-06-28 | 2020-12-08 | 浙江京新药业股份有限公司 | 氨基甲酸酯衍生物及其制备方法和用途 |
| JP2019163298A (ja) * | 2019-05-22 | 2019-09-26 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ | 禁煙の促進 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| CN114667964B (zh) * | 2020-12-24 | 2023-11-14 | 中国科学院脑科学与智能技术卓越创新中心 | 一种非人灵长类药物成瘾性评估的方法与应用 |
| JP2024516421A (ja) * | 2021-05-05 | 2024-04-15 | マインド メディシン， インコーポレイテッド | Ｍｄｍａ鏡像異性体 |
| CN121620365A (zh) | 2023-06-29 | 2026-03-06 | 艾克萨姆治疗股份有限公司 | 向哺乳期妇女施用索安非托的方法 |
| WO2026125068A1 (en) | 2024-12-10 | 2026-06-18 | Noucor Health, S.A. | Process to obtain solriamfetol hydrochloride |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) * | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| US5756817C1 (en) * | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173862B1 (ko) * | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| KR0173863B1 (ko) * | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2240060C (en) * | 1996-10-10 | 2007-07-17 | Sk Corporation | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same |
| AU4674797A (en) * | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| KR19980026988U (ko) * | 1996-11-13 | 1998-08-05 | 김무 | 다용도 드레인밸브 |
| TW402591B (en) | 1997-07-11 | 2000-08-21 | Janssen Pharmaceutica Nv | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| KR20010043032A (ko) | 1998-04-28 | 2001-05-25 | 도모따께 다께시 | 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체 |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| EP1390034A4 (en) | 2001-04-03 | 2005-07-13 | Merck & Co Inc | N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS |
| CA2449249A1 (en) | 2001-06-12 | 2002-12-19 | Merck & Co., Inc. | Nr2b receptor antagonists for the treatment or prevention of migraines |
| WO2004026868A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Japan Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| PL1664036T3 (pl) | 2003-09-03 | 2012-04-30 | Pfizer | Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 |
| US20050080268A1 (en) * | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| MX2007012463A (es) | 2005-04-08 | 2007-11-07 | Pfizer Prod Inc | Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i. |
| PL1890684T3 (pl) * | 2005-06-08 | 2014-05-30 | Sk Biopharmaceuticals Co Ltd | Leczenie zaburzeń snu i czuwania |
| EP1928451B1 (en) * | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
| US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
-
2009
- 2009-06-26 US US12/492,566 patent/US8232315B2/en active Active
-
2010
- 2010-06-10 ES ES10792277T patent/ES2766272T3/es active Active
- 2010-06-10 BR BRPI1015064A patent/BRPI1015064A2/pt not_active Application Discontinuation
- 2010-06-10 JP JP2012517372A patent/JP5650208B2/ja active Active
- 2010-06-10 AU AU2010263469A patent/AU2010263469B2/en active Active
- 2010-06-10 ES ES19163769T patent/ES2853730T3/es active Active
- 2010-06-10 EP EP19163769.3A patent/EP3552604B1/en active Active
- 2010-06-10 PL PL10792277T patent/PL2445489T3/pl unknown
- 2010-06-10 KR KR1020117031291A patent/KR101461567B1/ko active Active
- 2010-06-10 EP EP10792277.5A patent/EP2445489B1/en active Active
- 2010-06-10 WO PCT/KR2010/003742 patent/WO2010150995A2/en not_active Ceased
- 2010-06-10 CA CA2764665A patent/CA2764665C/en not_active Expired - Fee Related
- 2010-06-10 CN CN201080038115.XA patent/CN102695502B/zh active Active
- 2010-06-10 RU RU2011150654/15A patent/RU2535046C2/ru active
- 2010-06-10 DK DK10792277.5T patent/DK2445489T3/da active
- 2010-06-10 CN CN201410659089.2A patent/CN104490859B/zh active Active
- 2010-06-10 MX MX2011013201A patent/MX2011013201A/es active IP Right Grant
- 2010-06-24 TW TW099120577A patent/TWI483719B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011150654A (ru) | 2013-08-10 |
| KR20120028342A (ko) | 2012-03-22 |
| HK1209058A1 (en) | 2016-03-24 |
| CN102695502B (zh) | 2014-12-24 |
| HK1176285A1 (en) | 2013-07-26 |
| EP3552604B1 (en) | 2020-12-16 |
| WO2010150995A2 (en) | 2010-12-29 |
| CN104490859B (zh) | 2017-09-22 |
| DK2445489T3 (da) | 2020-01-27 |
| RU2535046C2 (ru) | 2014-12-10 |
| TW201103531A (en) | 2011-02-01 |
| EP2445489A2 (en) | 2012-05-02 |
| CA2764665C (en) | 2018-07-03 |
| JP5650208B2 (ja) | 2015-01-07 |
| US20100331332A1 (en) | 2010-12-30 |
| JP2012531405A (ja) | 2012-12-10 |
| CN104490859A (zh) | 2015-04-08 |
| CA2764665A1 (en) | 2010-12-29 |
| BRPI1015064A2 (pt) | 2016-04-19 |
| KR101461567B1 (ko) | 2014-11-26 |
| ES2766272T3 (es) | 2020-06-12 |
| AU2010263469A1 (en) | 2012-01-19 |
| MX2011013201A (es) | 2012-03-07 |
| CN102695502A (zh) | 2012-09-26 |
| ES2853730T3 (es) | 2021-09-17 |
| TWI483719B (zh) | 2015-05-11 |
| AU2010263469B2 (en) | 2015-02-05 |
| EP3552604A1 (en) | 2019-10-16 |
| US8232315B2 (en) | 2012-07-31 |
| EP2445489B1 (en) | 2019-10-30 |
| EP2445489A4 (en) | 2013-05-29 |
| WO2010150995A3 (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262668A (en) | Preparations for the treatment of Gaucher disease | |
| GB2469580B (en) | Delivery method and compositions | |
| EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
| PT3708178T (pt) | Peptídeo para uso ao prevenir ou tratar a degeneração macular | |
| IL239918A0 (en) | Preparations for the treatment of colitis | |
| IL215932A0 (en) | Compositions and methods for treating burns | |
| IL216374A0 (en) | Compositions and methods for drug delivery | |
| BRPI1015064A2 (pt) | composições para tratar vício de droga e comportamento relacionado ao vício | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| IL218212A0 (en) | Therapeutic methods and compositions | |
| ZA201008597B (en) | Methods and compositions for enhanced delivery of macromolecules | |
| GB0903299D0 (en) | Composition and methods | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| GB0912468D0 (en) | Composition and method | |
| IL216146A0 (en) | Methods and compositions for treating lupus | |
| IL210840A0 (en) | Methods and compositions for treating and preventing autoimmune diseases | |
| ZA201203060B (en) | Composition and method of delivery | |
| IL218726A0 (en) | Methods and pharmaceutical compositions for treating down syndrome | |
| EP2461870A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| GB0901494D0 (en) | Compositions and Methods | |
| EP2512504A4 (en) | COMPOSITION AND THERAPEUTIC METHOD | |
| EP2462131A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID | |
| ZA201209537B (en) | Pharmaceutical composition for treating drug addiction | |
| GB0901667D0 (en) | Composition and method | |
| IL219215A0 (en) | Compositions and methods for treating aspergillosis |